Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 6;12(1):e0169272.
doi: 10.1371/journal.pone.0169272. eCollection 2017.

The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study

Veronika Seebacher  1 , Alexander Reinthaller  1   2 , Heinz Koelbl  1 , Nicole Concin  3 , Regina Nehoda  3 , Stephan Polterauer  1   2
Affiliations

The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study

Veronika Seebacher et al. PLoS One. .

Abstract

Objective: The aim of the present study was to investigate the prognostic role of the duration of adjuvant chemotherapy in patients with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC).

Materials and methods: Within the present study we retrospectively evaluated the data of 165 consecutive patients with EOC treated with primary surgery followed by six completed cycles of platinum-taxan based intravenous adjuvant chemotherapy. Medians of total duration of chemotherapy were compared with clinical-pathological parameters. Patients were stratified into four risk groups according to the delay in days of total duration of chemotherapy, and univariate and multivariable survival analyses were performed.

Results: The median duration of six completed cycles of chemotherapy comprised 113 days (IQR 107-124 days). Uni- and multivariable survival analyses revealed a delay of total duration of chemotherapy of at least 9 days to be associated with progression-free (PFS), cancer-specific (CSS) and overall survival (OS). Hazard ratios (HR), confidence intervals (95% CI) and p-values for PFS, CSS and OS due to delay of chemo-duration were 2.9 (1.6-5.4; p = 0.001), 2.9 (1.3-6.2; p = 0.008) and 2.6 (1.3-5.4; p = 0.008), respectively. Prolonged total chemo-duration was associated with the amount of postoperative residual disease (p = 0.001) and the patients' age (p = 0.03).

Conclusion: The present study suggests a prolonged duration of adjuvant chemotherapy after primary surgery to adversely affect PFS, CSS and OS in patients with EOC. Yet larger studies are required to validate our results.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flowchart.
The process of inclusion and exclusion of patients in order to find the sample of patients included in the present study (= 165).
Fig 2
Fig 2. Survival curves.
Kaplan Meier curves for patients stratified into risk groups according to the delay of total chemo-duration are given for progression-free (PFS), cancer-specific (CSS), and overall survival (OS) in figures A, B, and C, respectively. 5-year rates of PFS, CSS and OS for each risk group are given in the table below.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr, accessed on 01/08/2016.
    1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20(5):1248–59. 10.1200/jco.2002.20.5.1248 - DOI - PubMed
    1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003;21(17):3194–200. 10.1200/JCO.2003.02.153 - DOI - PubMed
    1. McGuire WP, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003;89(Suppl.3):S3–8. - PMC - PubMed
    1. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 Protocol 1. J Clin Oncol 2009;27(28):4642–8. 10.1200/JCO.2009.21.9691 - DOI - PubMed

MeSH terms